Mir-671-5p Blocks the Progression of Human Esophageal Squamous Cell Carcinoma by Suppressing FGFR2

Xiaoyan Li,Changjun Nie,Baoqing Tian,Xuan Tan,Wei Han,Jiakang Wang,Yuan Jin,Yadan Li,Xinyuan Guan,An Hong,Xiaojia Chen
DOI: https://doi.org/10.7150/ijbs.32429
2019-01-01
International Journal of Biological Sciences
Abstract:Esophageal cancer is the eighth most common malignant tumor worldwide, of which esophageal squamous cell carcinoma (ESCC) is the dominant histological subtype. A drug shortage for ESCC therapy triggered us to explore the roles of fibroblast growth factor receptor 2 (FGFR2) and its upstream regulator miR-671-5p in ESCC progression. We compared the levels of FGFR2 and miR-671-5p between human ESCC tissues and their matched normal esophageal tissues and found an association between higher levels of FGFR2 and lower levels of miR-671-5p in ESCC tissues. High levels of FGFR2 resulted in the activation of the ERK and AKT pathways and a promotion of ESCC progression. High levels of miR-671-5p specifically reduced the expression of FGFR2 and suppressed ESCC progression in both in vitro and in vivo models. Therefore, suppressing FGFR2 and enhancing miR-671-5p expression may be the right approaches for ESCC therapy.
What problem does this paper attempt to address?